摘要
目的探讨帕利哌酮治疗急性期精神分裂症的临床疗效及安全性。方法急性期精神分裂症患者80例,随机分为治疗组和对照组各40例,分别给予帕利哌酮与齐拉西酮治疗,观察8周,分别于治疗前和治疗后第1,2,4,8周末采用阳性与阴性症状量表(PANSS)评定疗效;以治疗时出现的不良反应症状量表(TESS)评定不良反应。结果至研究终点,两组PANSS总分及各因子分均较治疗前明显下降(P<0.01);组间比较第1,2周末治疗组PANSS总分及阳性症状分均好于对照组(P<0.05)。两组有效率分别为67.5%,65.0%(P>0.05)。治疗组催乳素水平明显升高,对照组则无明显变化,差异有统计学意义(P<0.01)。治疗组肝功能异常的发生率明显低于对照组(P<0.05);两组均未出现严重不良反应。结论帕利哌酮治疗急性期精神分裂症临床疗效可靠,起效快,安全性好。
Objective To investigate the efficacy and safety of paliperidone in treating acute schizophrenia.Methods Eighty patients with acute schizophrenia were randomly assigned to the test group（paliperidone,n=40） and control group（ziprasidone,n=40）,who were administrated with paliperidone and ziprasidone,respectively,and were studied for 8 weeks.The clinical efficacy was evaluated with the Positive and Negative Syndrome Scale（PANSS） before and 1,2,4,8 weeks after treatment.Side effects were assessed with the Treatment Emergent Symptom Scale（TESS）.Results The total score of PANSS and each point in the two groups were notably decreased（P〈0.01） after treatment compared with that before treated.The total scores of PANSS and positive symptoms in the treatment group were significantly better than those in the control by the end of the 1st and 2nd weekends（P〈0.05）.The effective rate of the two groups was 67.5% and 65.0 %,respectively（P〉0.05）.The serum prolactin level in the test group was increased significantly after treatment（P〈0.01）,while which exhibited no significant change in the control group and there was significant difference between two groups.The incidence of abnormal liver function in treatment group was obviously lower than that in the control group（P〈0.05）.There were no severity adverse effects in both groups.Conclusion Paliperidone shows reliable clinical efficacy,quick effect and safety for treating acute schizophrenia.
出处
《医药导报》
CAS
北大核心
2012年第9期1150-1153,共4页
Herald of Medicine
